GlassScriptPhysician profile
Arthur Lee Cabales
NPI 1407859705
$13,175.41
in general payments reported to CMS, 2019-2025
36 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $1,801 · 2021: $2,326 · 2022: $1,626 · 2023: $1,550 · 2024: $1,835 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,603.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,664.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,489.96 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,743.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,111.87 | 2019-2025 | Jardiance |
| Ironwood Pharmaceuticals, INC | $631.41 | 2020-2024 | Linzess |
| Abbvie INC. | $480.18 | 2019-2024 | Viberzi, Linzess |
| Lilly USA, LLC | $462.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $355.37 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $347.84 | 2019-2022 | |
| Amgen INC. | $292.64 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $238.20 | 2019-2022 | |
| Pfizer INC. | $232.87 | 2019-2025 | |
| Genzyme Corporation | $209.76 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $178.34 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $175.00 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $165.73 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Allergan, INC. | $164.77 | 2020 | |
| Edwards Lifesciences Corporation | $142.87 | 2025 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.98 | 2019-2025 | Xifaxan |
| Acorda Therapeutics, INC | $128.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $127.72 | 2025 | Voquezna |
| Hikma Pharmaceuticals USA | $95.96 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.85 | 2022-2024 | |
| Nabriva Therapeutics, Plc | $77.86 | 2021 | |
| Exact Sciences Corporation | $75.51 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $72.59 | 2021-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $54.84 | 2019-2021 | |
| Dexcom, INC. | $47.64 | 2025 | Dexcom G6 Transmitter |
| Vivus LLC | $34.00 | 2023 | Qsymia |
| Kowa Pharmaceuticals America, INC. | $27.44 | 2019 | |
| Nestle Healthcare Nutrition INC. | $26.10 | 2021 | |
| Eyevance Pharmaceuticals LLC | $25.93 | 2021 | |
| Amarin Pharma, INC. | $25.27 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $22.89 | 2025 | Purified Cortrophin Gel |
| Corcept Therapeutics | $13.21 | 2024 | Korlym |
| Eisai INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Cabales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.